Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: October 14, 2019

Epichem New CEO and Board Additions

News & Announcements 2019By Richard Mollard October 14, 2019

191014_Epichem New CEO and Board Additions

Recent Articles

3 March, Brisbane Animal Referral Hospital Joins PharmAust Phase II Dog Cancer Trial
March 3, 2020
29 February, Top 20 Shareholders
February 29, 2020
28 Feb, Appendix 4D & Half Year Report
February 28, 2020
31 January 2020, Top 20 Shareholders
January 31, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. ASX: $PAA

PharmAust @PharmAust·

Calling dogs with lymphoma for promising anti-cancer drug clinical trial | The National Tribune https://www.nationaltribune.com.au/calling-dogs-with-lymphoma-for-promising-anti-cancer-drug-clinical-trial/

Reply on Twitter 1239340304542523394 Retweet on Twitter 12393403045425233943 Like on Twitter 123934030454252339412 Twitter 1239340304542523394

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions